STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders,...

Full description

Bibliographic Details
Main Authors: Erickson, Craig A. (Author), Veenstra-Vanderweele, Jeremy M. (Author), Melmed, Raun D. (Author), McCracken, James T. (Author), Ginsberg, Lawrence D. (Author), Sikich, Linmarie (Author), Scahill, Lawrence (Author), Cherubini, Maryann (Author), Zarevics, Peter (Author), Walton-Bowen, Karen (Author), Carpenter, Randall L. (Author), Wang, Paul P. (Author), King, Bryan H. (Author), Bear, Mark (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences (Contributor), Picower Institute for Learning and Memory (Contributor)
Format: Article
Language:English
Published: Springer-Verlag, 2015-03-03T21:25:15Z.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items